Biocon Biologics to Acquire Viatris’ Biosimilars Assets For $ 3.335 Billion
▪ Biocon Biologics Limited’s (BBL) acquisition of Viatris’ rights in biosimilars assets,…
Biocon Partners With Adagio To Manufacture Novel Antibody For Treatment Of Covid-19
Biocon Biologics to manufacture and commercialise a broadly neutralising antibody for India…
Biocon Biologics partners with Voluntis for digital therapeutics for diabetes patients
Amritsar, NFAPost: Biocon Biologics has announced a global collaboration agreement with Voluntis…
